Free preview. Sign up free to see the team, full portfolio, ownership chain, and shareholding history.
Sign up freePricing

Forbion Ventures Fund Vi Coã¶Peratief U.A. investment portfolio

Forbion Ventures Fund Vi Coã¶Peratief U.A. has made numerous investments in companies such as Verdiva Bio, Purespring Therapeutics, and Loqus23 Therapeutics within the Biotech sector.

vc
Portfolio
3
Team
0

Portfolio (3)

CompanySectorCitySourceLast confirmed on
Loqus23 Therapeutics Limited
LoQus23 Therapeutics Ltd is a biotechnology company developing small‑molecule somatic expansion inhibitors for Huntington’s disease and other triplet‑repeat expansion neurodegenerative disorders. Its lead programme is an allosteric MSH3 inhibitor that is scheduled to enter the clinic in 2026.
BiotechHealth Tech
Great AbingtonConfirmed2026-03-28
Purespring Therapeutics Limited
Purespring Therapeutics is a London‑based precision‑nephrology company that develops adeno‑associated viral (AAV) gene therapies targeting the podocyte to halt or reverse chronic kidney disease. Its platform is focused on preserving kidney function for patients with renal disorders.
Healthcare & Life SciencesLondonConfirmed2026-03-31

Sign up to see the full portfolio

+1 more company

Sign up

Shareholding changes (3)

Forbion Ventures Fund Vi Coã¶Peratief U.A.'s positions across portfolio companies
2026
2025

Sign up free to see when this investor has bought or sold shares.

+1 more change

Sign up

Articles (1)